These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 36006861)

  • 1. Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy.
    Fang Y; Wang J; Zhao M; Zheng Q; Ren C; Wang Y; Zhang J
    J Med Chem; 2022 Sep; 65(17):11454-11477. PubMed ID: 36006861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.
    Lin J; Jin J; Shen Y; Zhang L; Gong G; Bian H; Chen H; Nagle DG; Wu Y; Zhang W; Luan X
    Theranostics; 2021; 11(17):8337-8349. PubMed ID: 34373745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
    Alabi SB; Crews CM
    J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing targeted protein degradation for metabolic diseases therapy.
    Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
    Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
    Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
    Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted protein degradation in cancers: Orthodox PROTACs and beyond.
    Li J; Chen X; Lu A; Liang C
    Innovation (Camb); 2023 May; 4(3):100413. PubMed ID: 37033156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design.
    Chen Y; Liu F; Pal S; Hu Q
    Chem Soc Rev; 2024 Sep; 53(19):9582-9608. PubMed ID: 39171633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging degrader technologies engaging lysosomal pathways.
    Ding Y; Xing D; Fei Y; Lu B
    Chem Soc Rev; 2022 Oct; 51(21):8832-8876. PubMed ID: 36218065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
    Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
    Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions.
    Kamaraj R; Ghosh S; Das S; Sen S; Kumar P; Majumdar M; Dasgupta R; Mukherjee S; Das S; Ghose I; Pavek P; Raja Karuppiah MP; Chuturgoon AA; Anand K
    Bioconjug Chem; 2024 Aug; 35(8):1089-1115. PubMed ID: 38990186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifaceted targeted protein degradation systems for different cellular compartments.
    Zorca CE; Fallahi A; Luo S; Eldeeb MA
    Bioessays; 2022 Jun; 44(6):e2200008. PubMed ID: 35417040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted protein degradation in drug development: Recent advances and future challenges.
    Song J; Hu M; Zhou J; Xie S; Li T; Li Y
    Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress of small molecules for targeted protein degradation: PROTACs and other technologies.
    Zhao HY; Xin M; Zhang SQ
    Drug Dev Res; 2023 Apr; 84(2):337-394. PubMed ID: 36606428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders.
    Tomoshige S; Ishikawa M
    Angew Chem Int Ed Engl; 2021 Feb; 60(7):3346-3354. PubMed ID: 32410219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives.
    Inuzuka H; Liu J; Wei W; Rezaeian AH
    Acta Mater Med; 2022; 1(1):24-41. PubMed ID: 35237768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances of targeted protein degradation technology and its applications in diseases therapy].
    Chen S; Yang H; Jiang J; Yu S; Li T; Ge S
    Sheng Wu Gong Cheng Xue Bao; 2021 Nov; 37(11):3915-3932. PubMed ID: 34841795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway.
    Cassidy K; Zhao H
    Biochemistry; 2023 Feb; 62(3):580-587. PubMed ID: 34569233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted protein degradation: A promise for undruggable proteins.
    Samarasinghe KTG; Crews CM
    Cell Chem Biol; 2021 Jul; 28(7):934-951. PubMed ID: 34004187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation.
    Ruffilli C; Roth S; Rodrigo M; Boyd H; Zelcer N; Moreau K
    ACS Pharmacol Transl Sci; 2022 Oct; 5(10):849-858. PubMed ID: 36268122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.